Discovery, Refinement, Validation.
Lanterne Dx (LDX) is a full-service histopathology CRO offering discovery, translational, and clinical biomarker services. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization, and validation. Key capabilities include immunohistochemistry (IHC), immunofluorescence (IF), multiplexing, in situ hybridization (ISH), fluorescence in situ hybridization (FISH), and a wide range of microscopic applications. These services are complemented by both qualitative and quantitative pathology evaluations, advanced image analysis, and comprehensive data analysis—all designed to streamline and accelerate drug development efforts.
At Lanterne Dx, we are dedicated to being your trusted partner throughout the drug development journey, offering expert guidance from preclinical research to clinical applications.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 2108 55th Street,
- Industry
- Research
- Website
- https://lanternedx.com/
- HQ
- Boulder, CO
Lanterne Dx Questions
Lanterne Dx's website is https://lanternedx.com/
Lanterne Dx's LinkedIn profile is https://www.linkedin.com/company/lanternedx
Lanterne Dx has
11 employees.
View email and phone details for 11
employees at Lanterne Dx.
Lanterne Dx's industry is
Research
Lanterne Dx's top competitors are
Edgewise Therapeutics,
Flagship Biosciences, Inc.,
Akoya Biosciences, Inc.,
Bruker Spatial Biology,
Biocare Medical,
Ultivue By Vizgen,
Molecular Instruments,
Canopy Biosciences,
Kbi Biopharma,
Biodesix, Inc..
Lanterne Dx's categories are Research
Lanterne Dx's founding year is 2019
